Targeting transcription factors that act as master regulators of cancer progression has long been an important goal in oncology drug discovery. Among the most prominent of these are hypoxia-inducible factors 1 and 2 (HIF‑1 and HIF‑2), which orchestrate broad transcriptional programs that drive tumor growth, angiogenesis, metastasis, and immune evasion. Despite their importance, effectively targeting [...]

November 20, 2025, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, is excited to announce the hiring of Steven Gossert, Ph.D. as Applications Scientist, Computational Drug Design. Over the last several years, Steven has worked as a postdoctoral modeling scientist in Drug Product Development at [...]

High-throughput, physics-based simulations delivering near-FEP accuracy, interpretability, and speed — a retrospective study on the challenging KRAS G12D target. KRAS mutations—especially the G12D variant—are among the most high-value, but historically “undruggable,” targets in oncology. Understanding where ligands bind, how strongly they bind, and how structural modifications affect affinity is key to advancing potent inhibitors. [...]

We are thrilled to unveil SilcsBio Version 2024.2, a dedicated update focusing exclusively on enhancing our Graphical User Interface (GUI). This release is packed with features designed to make your molecular visualization and analysis more intuitive and efficient. See below for all the new features.   Learn More About the Update: For a detailed overview of these [...]

We are thrilled to announce the launch of the CGenFF Web App by SilcsBio. To celebrate this milestone, we recently hosted a webinar that delved into the capabilities and applications of the CGenFF platform. What is CGenFF? CGenFF, short for CHARMM General Force Field, represents a force field parameterization program designed to enhance accuracy and [...]